![]() In October 2014, following a successful pre-clinical demonstration of the combination vaccine regimen of its multivalent MVA-BN Filovirus vaccine and Crucell/Janssen's AdVac technology based on adenoviral vectors, Bavarian Nordic joined efforts with Crucell Holland B.V., one of the Janssen Pharmaceuticals companies of Johnson & Johnson to develop and manufacture this vaccine regimen intended for emergency use to help contain the outbreak in West Africa. ![]() The company has worked for several years with the NIAID on the development of a filovirus vaccine for Ebola and Marburg hemorrhagic fever diseases. Ebola vaccine development and production This technology formed the basis of the company's lead oncology product candidates, Prostvac and CV-301. The poxvirus-based immunotherapy can be modified to encode different tumor-associated antigens such as Prostate-specific antigen (PSA), Carcinoembryonic antigen (CEA) and/or Mucin 1 (MUC1), which are all tumor markers that are overexpressed in various cancers. Vaccinia-fowlpox-TRICOM is a sequential prime-boost therapy based on vaccinia and fowlpox in combination with three co-stimulatory molecules (TRICOM). Vaccinia-fowlpox-TRICOM Ī second poxvirus-based technology is employed in most of the company's cancer immunotherapies, and was in-licensed as part of a collaboration with the National Cancer Institute (NCI). The vaccine is being deployed worldwide to combat the 2022 monkeypox outbreak, leading to concerns over vaccine nationalism and hoarding by countries with pre-existing contracts. Strategic National Stockpile as well as other government stockpiles. The vaccine was supplied for emergency use to the U.S. Developed as the non-replicating smallpox and monkeypox vaccine, MVA-BN is approved in Canada as Imvamune, in the European Union, as Imvanex, and the United States as MVA-BN is characterized by the inability to replicate in human cells, contrary to other vaccinia-based vaccines, which may replicate in humans, thus potentially causing severe and life-threatening side effects. It is derived from the Modified vaccinia Ankara virus. MVA-BN is a proprietary technology developed by Bavarian Nordic. The company uses viral vectors in its research and development. The company has a research and development facility in Martinsried, Germany, and offices in Zug, Switzerland, and Morrisville, North Carolina. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm. Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |